天堂国产午夜亚洲专区-少妇人妻综合久久蜜臀-国产成人户外露出视频在线-国产91传媒一区二区三区

當(dāng)前位置:主頁 > 醫(yī)學(xué)論文 > 泌尿論文 >

血液凈化治療患者血管通路使用情況分析

發(fā)布時間:2019-07-01 17:58
【摘要】:研究一維持性血液透析患者血管通路使用情況分析目的:明確我們中心血液透析患者首次和目前血管通路使用情況及影響因素。方法:2015年7月~2015年12月維持性血液患者納入研究。資料收集來自于本中心透析患者登記本、海泰電子資料庫、血液透析記錄單以及問卷調(diào)查。收集的資料包括:年齡、性別、開始進(jìn)入血液透析基線資料、原發(fā)病、透析齡及合并癥(包括糖尿病、高血壓)等。無滌綸套導(dǎo)管和帶隧道帶Cuff導(dǎo)管置管部位、留置時間、并發(fā)癥等。自體或移植動靜脈內(nèi)瘺情況,包括內(nèi)瘺建立部位、成熟時間、使用壽命及并發(fā)癥等。此外,收集血管通路變更情況及患者實(shí)驗(yàn)室檢查結(jié)果等。結(jié)果:294例患者,男性189例(64.3%),女性105例(35.7%),年齡53.2±15.1歲(15~87歲),透析齡6.2(0.3~32)年。原發(fā)病以原發(fā)性腎小球腎炎為主。首次透析血管通路動靜脈內(nèi)瘺56例(19.0%),無滌綸套導(dǎo)管235例(79.9%)。首次血液透析未使用內(nèi)瘺的主要原因:就診時即診斷尿毒癥占55.9%,無人告知占23.0%。目前血管通路動靜脈內(nèi)瘺占91.8%,帶隧道帶Cuff導(dǎo)管占6.12%。年齡在65歲以上患者動靜脈內(nèi)瘺使用率開始減少,導(dǎo)管使用率增加。透析齡小于2年患者,帶隧道帶Cuff導(dǎo)管使用率最高,透析齡20年以上者血管通路均為動靜脈內(nèi)瘺。無論是無滌綸套導(dǎo)管,還是長期帶隧道帶Cuff導(dǎo)管置管部位主要以頸內(nèi)靜脈為主,感染發(fā)生率較低,分別為1.09/1000導(dǎo)管日和2.03/1000導(dǎo)管日。自體動靜脈內(nèi)瘺部位主要以左橈動脈-頭靜脈為主(75.4%),首選端端吻合。首次透析開始前和開始后內(nèi)瘺手術(shù)成功者,除在內(nèi)瘺成熟時間上存在差別外,在性別、年齡、手術(shù)部位、血流量、內(nèi)瘺使用壽命上均無明顯統(tǒng)計(jì)學(xué)差異。動靜脈內(nèi)瘺早期并發(fā)癥主要是術(shù)后血栓形成,晚期并發(fā)癥主要包括內(nèi)瘺堵塞、動脈瘤樣擴(kuò)張或動脈瘤形成、血流量不足以及肢體水腫等。2例肢體水腫患者右側(cè)鎖骨下靜脈與上腔靜脈交界處狹窄,經(jīng)球囊擴(kuò)張及放置血管支架后,血管再通、肢體水腫消失。移植物動靜脈內(nèi)瘺使用較低,僅1例患者。結(jié)論:通過橫斷面調(diào)查明確在我們中心首次血液透析血管通路以無滌綸套導(dǎo)管為主,目前血管通路以動靜脈內(nèi)瘺為主。導(dǎo)管置管部位主要以頸內(nèi)靜脈為主,并且感染發(fā)生率較低。動靜脈內(nèi)瘺部位以左側(cè)橈動脈-頭靜脈為主,首選端端吻合。動靜脈內(nèi)瘺早期并發(fā)癥主要是術(shù)后血栓形成,晚期并發(fā)癥主要包括內(nèi)瘺堵塞、動脈瘤樣擴(kuò)張或動脈瘤形成、血流量不足以及肢體水腫等。遺憾的是,我們中心血液透析患者移植物動靜脈內(nèi)瘺使用較少,目前尚未普及。研究二:連續(xù)性腎臟替代治療患者血管通路使用情況分析目的:明確我們中心連續(xù)性腎臟替代治療患者血管通路使用及并發(fā)癥情況。方法:2014年4月~2014年10月,收集本中心連續(xù)性腎臟替代治療患者的資料,包括人口學(xué)資料、原發(fā)病、收治科室、血壓、心率、SOFA評分、APACHE II評分、有無使用免疫抑制劑、有無機(jī)械通氣、連續(xù)性腎臟替代治療方式、血管通路選擇、無滌綸套導(dǎo)管置管部位、置管時間、血流量,有無重新置管、重新置管部位、重新置管后導(dǎo)管使用時間、導(dǎo)管護(hù)理、導(dǎo)管累計(jì)使用時間、導(dǎo)管功能失功及導(dǎo)管感染等。此外,還收集患者血管通路變更情況及實(shí)驗(yàn)室檢查結(jié)果等。結(jié)果:292例患者符合條件入選本研究。其中,男性175例(59.9%),女性117例(40.1%),年齡50.8±18.6歲(12~94歲)。CRRT患者以AKI、MODS以及SIRS患者為主。血管通路:280例患者選擇無滌綸套導(dǎo)管,所占比例為95.9%,11例患者使用動靜脈內(nèi)瘺僅占3.77%,1例患者使用長期帶滌綸套帶隧道導(dǎo)管。無滌綸套導(dǎo)管置管部位主要為右側(cè)頸內(nèi)靜脈(54.3%),其次為右側(cè)股靜脈(30.7%)和左側(cè)股靜脈(13.2%)。其中,內(nèi)科和急診科患者置管部位主要是右側(cè)頸內(nèi)靜脈,外科患者主要是右側(cè)和左側(cè)股靜脈;此外,CRRT方式,連續(xù)性靜脈靜脈血液濾過患者置管部位以股靜脈為主,連續(xù)性靜脈靜脈血液透析以右側(cè)頸內(nèi)靜脈為主。32例患者(11.4%),在CRRT治療過程中需要重新置管,共計(jì)51次,平均重新置管1.59±0.98次,最高重新置管次數(shù)4次。重新置管原因主要為感染和導(dǎo)管功能失功;重新置管部位以左側(cè)股靜脈為主(52.9%),重新置管部位與首次置管部位相同者僅占21.6%。導(dǎo)管功能失功,占全部患者的7.14%,占全部置管總數(shù)的11.8%,導(dǎo)管功能失功的中位時間5天,平均使用時間8.95天,原因主要為導(dǎo)管內(nèi)血栓(17.9%)和導(dǎo)管血流量不足(82.1%),多因素分析導(dǎo)管功能失功的主要風(fēng)險因素為CRRT累計(jì)時間和血Hb水平。此外,導(dǎo)管感染發(fā)生的平均時間為置管后10.7天,導(dǎo)管感染發(fā)生率為7.19/1000導(dǎo)管日,導(dǎo)管感染發(fā)生率股靜脈高于頸內(nèi)靜脈,外科患者高于內(nèi)科患者。影響導(dǎo)管感染的主要因素是導(dǎo)管累計(jì)使用時間和血清ALB水平。結(jié)論:通過橫斷面調(diào)查發(fā)現(xiàn)我們中心CRRT治療患者血管通路主要選擇無滌綸套導(dǎo)管,置管部位以右側(cè)頸內(nèi)靜脈為主,部分患者需要重新置管。導(dǎo)管功能失功主要風(fēng)險因素是CRRT累計(jì)時間和血Hb水平。導(dǎo)管感染發(fā)生的平均時間為置管后10.7天,導(dǎo)管感染發(fā)生率為7.19/1000導(dǎo)管日。影響導(dǎo)管感染的主要因素是導(dǎo)管累計(jì)使用時間和血清ALB水平。
[Abstract]:The purpose of the study on the use of vascular access in a maintenance hemodialysis patient is to identify the first and present use of vascular access in our central hemodialysis patients and the factors affecting them. Method: The maintenance hemodialysis patients were included in the study from July 2015 to December 2015. The data collected from this central dialysis patient's registry, the Haitai electronic database, the hemodialysis record sheet, and the questionnaire. The data collected included age, sex, baseline data from the beginning to the hemodialysis, the original onset, the dialysis age, and the comorbidities, including diabetes, hypertension, and the like. No polyester jacket catheter and catheter with cuff catheter with tunnel, retention time, complication, etc. Autologous or grafted arteriovenous contraindications, including the establishment site, the mature time, the service life and the complications, etc. In addition, the change of the vascular access and the results of the patient's laboratory tests were collected. Results: There were 294 patients,189 (64.3%),105 (35.7%), 53.2-15.1 (15-87), and 6.2 (0.3-32) years. The primary glomerular nephritis is the main disease. In the first time,56 cases (19.0%) and 235 cases (79.9%) of the vascular access were treated. The primary reason for the first hemodialysis not to be used was: the diagnosis of uremia was 55.9% at the time of the visit, and no one was informed of 23.0%. In the present, 91.8% of the vascular access and the Cuff catheter with the tunnel account for 6.12%. In patients with age over 65 years of age, the rate of use of vascular access was reduced and the rate of catheter usage increased. In patients with dialysis age less than 2 years, the use rate of Cuff catheter with tunnel was the highest, and the vascular access of over 20 years of dialysis was the inside of the artery and vein. There were mainly internal jugular vein and internal jugular vein, and the incidence of infection was low, 1.09/1000 catheter days and 2.03/1000 catheter days, respectively. The main part of the internal jugular vein of the vein was mainly the left inferior artery-head vein (75.4%), and the first-choice end-end anastomosis. There was no significant difference in sex, age, operation site, blood flow and internal life of the first time before and after the first dialysis. The early complications of the early complications of the AVMs are the postoperative thrombosis, and the late complications mainly include internal occlusion, aneurysm-like expansion or aneurysm formation, insufficient blood flow, and limb edema. After the balloon was expanded and the stent was placed, the vessel was recanalized and the edema of the limb disappeared. The use of the graft and arterio-venous system was low, with only one patient. Conclusion: Through the cross-sectional investigation, the first hemodialysis vascular access in our center is dominated by the non-polyester sleeve catheter, and the current vascular access is mainly in the vein of the vein. The catheter insertion site was mainly internal jugular vein, and the incidence of infection was lower. The site of the vein of the arteriovenous is the main artery-head vein of the left side, and the preferred end is in good agreement. The early complications of the early complications of the arteriovenous malformation are the postoperative thrombosis, and the late complications mainly include internal occlusion, aneurysm-like expansion or aneurysm formation, insufficient blood flow, and limb edema. Unfortunately, in our central hemodialysis patients, the use of graft and vein is less, and is not yet available. Objective: To study the vascular access and complications of continuous renal replacement therapy in patients with continuous renal replacement therapy. Method: From April 2014 to October 2014, the data of the continuous renal replacement therapy in this center was collected, including the demographic data, the original incidence, the department, the blood pressure, the heart rate, the SOFA score, the APACHE II score, the presence or absence of the immunosuppressants, the presence or absence of mechanical ventilation, The method of continuous renal replacement therapy, the selection of the vascular access, the location of the catheter in the non-polyester sleeve catheter, the time of the catheter insertion, the blood flow, the presence or absence of the catheter, the location of the re-insertion, the time of the catheter after the re-placement, the catheter care, the cumulative time of use of the catheter, Catheter function loss of work and catheter infection, etc. In addition, that change of the vascular access of the patient and the result of laboratory examination were also collected. Results:292 patients were eligible for inclusion in this study. Of these,175 males (59.9%),117 females (40.1%), and 50.8 to 18.6 years (12 to 94 years). The patients with CRRT were AKI, MODS and SIRS. Vascular access:280 patients had the choice of PET-free catheter, the proportion was 95.9%, and 11 patients used AVMs for 3.77%, and one patient used long-term polyester sleeve with tunnel. There were mainly right internal jugular vein (54.3%) and right femoral vein (30.7%) and left femoral vein (13.2%). in that case of the internal medicine department and the emergency department, the catheter site is mainly the right internal jugular vein, and the surgical patient is mainly the right and left femoral veins; in addition, the CRRT method and the continuous vein venous hemofiltration patient are mainly provided with a femoral vein, The right internal jugular vein was the main.32 patients (11.4%) had to be re-inserted in the treatment of CRRT, with a total of 51 times, an average of 1.59 and 0.98 times, and the maximum number of re-insertion times was 4 times. The reason of the re-insertion is the function of the infection and the function of the catheter; the site of the re-insertion is the main (52.9%) of the left femoral vein, and the re-insertion site only accounts for 21.6% of the same person as the first place of the catheter. The function of the catheter was lost, accounting for 7.14% of all the patients, accounting for 11.8% of the total number of the tubes, the median time of the function of the catheter was 5 days, the mean time of use was 8.95 days, the reason was that the thrombus in the catheter (17.9%) and the blood flow of the catheter were not sufficient (82.1%). The main risk factors of the multi-factor analysis of the function loss of the catheter were the cumulative time of CRRT and the level of Hb. In addition, the mean time of catheter infection was 10.7 days after the placement of the tube, the incidence of catheter infection was 7.19/1000 catheter days, the incidence of catheter infection was higher than that of the internal jugular vein, and the surgical patient was higher than that of the medical patient. The main factors that affect the catheter infection are the cumulative use time of the catheter and the serum ALB level. Conclusion: Through the cross-sectional investigation, we find that the vascular access of the central CRRT is the main choice of the non-polyester-free catheter, and the site of the catheter is the right internal jugular vein, and some patients need to be re-inserted. The main risk factors of the function failure of the catheter are the CRRT accumulation time and the blood Hb level. The mean time for catheter infection was 10.7 days after placement and the incidence of catheter infection was 7.19/1000 catheter days. The main factors that affect the catheter infection are the cumulative use time of the catheter and the serum ALB level.
【學(xué)位授予單位】:第二軍醫(yī)大學(xué)
【學(xué)位級別】:博士
【學(xué)位授予年份】:2016
【分類號】:R692.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳侶林,徐秀蓉,周妤,郝惠文,劉俊,賈麗娟;急診血液透析不同血管通路的對比分析[J];中國廠礦醫(yī)學(xué);2005年03期

2 葉朝陽;;血管通路的功能評估[J];中國血液凈化;2007年07期

3 袁偉杰;;應(yīng)關(guān)注血管通路遠(yuǎn)期并發(fā)癥及其處理[J];中國血液凈化;2009年06期

4 蘇白海;付平;;充分認(rèn)識和面對建立永久性血管通路所面臨的挑戰(zhàn)[J];中國血液凈化;2009年07期

5 何雪花;;化療患者血管通路的護(hù)理管理[J];中國民間療法;2010年06期

6 李鳳君;足背動脈在暫時性血管通路中的應(yīng)用[J];張家口醫(yī)學(xué)院學(xué)報;1998年01期

7 龐慧華,錢家麒,張慶怡,黃佩文,張紀(jì)蔚,張皓;血透中永久性血管通路的功能監(jiān)測[J];上海第二醫(yī)科大學(xué)學(xué)報;2000年04期

8 王笑云;;要重視透析血管通路創(chuàng)建維護(hù)和并發(fā)癥的防治[J];中國血液凈化;2007年07期

9 孫曉萌;劉宏;劉必成;;血管通路感染的診治進(jìn)展[J];中國血液凈化;2013年06期

10 黃建業(yè),高賀通,姜建芳;化療用血管通路裝置在臨床中的應(yīng)用與護(hù)理[J];第二軍醫(yī)大學(xué)學(xué)報;1999年11期

相關(guān)會議論文 前10條

1 葉朝陽;;血管通路的功能評估[A];中華醫(yī)學(xué)會腎臟學(xué)分會2004年年會暨第二屆全國中青年腎臟病學(xué)術(shù)會議專題講座匯編[C];2004年

2 葉朝陽;華參;;血管通路的功能監(jiān)測[A];中華醫(yī)學(xué)會腎臟病學(xué)分會2006年學(xué)術(shù)年會專題講座[C];2006年

3 王笑云;;慢性血管通路選擇和并發(fā)癥防治[A];血液透析進(jìn)展學(xué)習(xí)班講義[C];2006年

4 馮玉珍;李采瓊;周婧;;維持性血液透析患者血管通路的并發(fā)癥及護(hù)理[A];全國內(nèi)科護(hù)理學(xué)術(shù)交流會議、全國心臟內(nèi)、外科護(hù)理學(xué)術(shù)交流會議、第9屆全國糖尿病護(hù)理學(xué)術(shù)交流會議、第9屆全國血液凈化護(hù)理學(xué)術(shù)交流會議論文匯編[C];2011年

5 Janet Pettit;;兒科&新生兒最佳血管通路選擇[A];全國兒科護(hù)理學(xué)術(shù)交流會議論文匯編[C];2012年

6 徐秋蘭;;血脂凈化治療中建立兩種血管通路的體會[A];第一屆全國疑難重型肝病大會、第四屆全國人工肝及血液凈化學(xué)術(shù)年會論文集[C];2008年

7 陳麗云;施素華;梁萌;許樹根;;兩種血管穿刺法對透析血管通路狹窄發(fā)生率的影響[A];第十一屆全國中西醫(yī)結(jié)合腎臟病學(xué)術(shù)會議論文匯編[C];2010年

8 張玉強(qiáng);陳順杰;徐成剛;葉朝陽;趙學(xué)智;;維持性血液透析患者疑難血管通路的選擇和應(yīng)用經(jīng)驗(yàn)[A];“中華醫(yī)學(xué)會腎臟病學(xué)分會2004年年會”暨“第二屆全國中青年腎臟病學(xué)術(shù)會議”論文匯編[C];2004年

9 吳紅艷;張樂;艾方;范志萍;李霞;;血液凈化者血管通路的管理[A];中華醫(yī)院管理學(xué)會血液凈化中心管理分會2004年會論文匯編[C];2004年

10 梅長林;;血管通路的選擇及并發(fā)癥防治[A];貴州省醫(yī)學(xué)會腎臟病學(xué)分會2008年學(xué)術(shù)年會論文匯編[C];2008年

相關(guān)重要報紙文章 前1條

1 付東紅 管九蘋;北京大學(xué)臨床腫瘤學(xué)院血管通路中心成立[N];中國醫(yī)藥報;2010年

相關(guān)博士學(xué)位論文 前1條

1 任紅旗;血液凈化治療患者血管通路使用情況分析[D];第二軍醫(yī)大學(xué);2016年

相關(guān)碩士學(xué)位論文 前4條

1 李劍瑩;維持性血液透析患者血管通路現(xiàn)狀及影響因素分析[D];安徽醫(yī)科大學(xué);2015年

2 楊艷麗;維持性血液透析患者血管通路建立和應(yīng)用情況的臨床調(diào)查研究[D];河北醫(yī)科大學(xué);2011年

3 張穎秋;維持性血透患者血管通路再循環(huán)測定方法的對比研究[D];第二軍醫(yī)大學(xué);2004年

4 丁燕平;兩種血管通路血液透析患者住院率及生存情況的比較[D];廣西醫(yī)科大學(xué);2015年



本文編號:2508688

資料下載
論文發(fā)表

本文鏈接:http://www.sikaile.net/yixuelunwen/mjlw/2508688.html


Copyright(c)文論論文網(wǎng)All Rights Reserved | 網(wǎng)站地圖 |

版權(quán)申明:資料由用戶443b5***提供,本站僅收錄摘要或目錄,作者需要刪除請E-mail郵箱bigeng88@qq.com